CPT2 and cancer: Specifically, elevation of Q2 or Q3, as seen in our cachectic cancer patient cohort loosing further weight compared with cachectic cancer patients maintaining or even gaining weight, represents an established marker for defective CPT II function39 in the clinical setting for newborn screening, which results in impaired β‐oxidation and/or liver ketogenesis.21